Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga· 47 minutes agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Cerevance receives milestone payment under Alzheimer's collaboration with Merck
Seeking Alpha· 3 hours agoPrivately held Cerevance receives milestone payment from Merck for Alzheimer's research...
Merck reports data from Phase III gastric cancer treatment trial
Clinical Trials Arena via Yahoo Finance· 11 hours agoMerck (MSD) has announced the final analysis findings from the Phase III KEYNOTE-811 clinical trial...
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 1 day agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Merck KGaA's Dividend Analysis
GuruFocus.com via Yahoo Finance· 3 days agoMerck KGaA (MKKGY) recently announced a dividend of $0.47 per share, payable on 2024-05-09, with the ex-dividend date set for 2024-04-29. As investors...
Is Merck Stock Fully Valued At $130?
Forbes· 2 days agoMerck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates. The growth was primarily driven by higher sales...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 3 hours agoMeanwhile, Moderna is expanding its efforts in cancer treatment. The company is partnered with Merck...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $143.00
ETF DAILY NEWS· 4 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) had its target price boosted by Truist Financial from $142.00 to $143.00 in a research report released on Friday, Benzinga reports ...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 3 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
